Table 3 Antimicrobial susceptibilities of the 61 CPE isolates (2011–2016, Reunion Island, France). a Two isolates harboured two carbapenemase-encoding genes: one K. pneumoniae isolate harboured blaNDM-1 and blaOXA-181, and one E. coli isolate harboured blaNDM-1 and blaVIM-2. b The clinical breakpoints for imipenem (0.125–4) were used to determine the susceptibility of the isolate of P. mirabilis. c Because of the intrinsic resistance of the P. mirabilis species to tigecycline, one isolate of P. mirabilis harbouring blaNDM-1 was excluded for the calculation of non-susceptibility rate of tigecycline. The PK/PD clinical breakpoints for tigecycline (EUCAST 2019; 0.5–0.5) were used to determine the susceptibility of other isolates than E. coli. d Because of the intrinsic resistance of the S. marcescens and P. mirabilis species to colistin, one isolate of P.mirabilis harbouring blaNDM-1 and 3 isolates of S.marcescens harbored blaIMP-10 were excluded for the calculation of non-susceptibility rate of colistin (N.D.: not determined)
Antimicrobials | Carbapenemase-encoding genes (% of non-susceptible isolates) | MIC Range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | |||||
|---|---|---|---|---|---|---|---|---|---|
blaNDMa | blaIMI | blaIMP-10 | blaOXA-181 | Total | Min. | Max. | |||
(n = 50) | (n = 7) | (n = 3) | (n = 1) | (n = 61) | |||||
Ertapenem | 96 | 71.4 | 100 | 0 | 91.8 | 0.25 | 32 | 8 | 32 |
Imipenem | 66b | 100 | 100 | 0 | 70.5b | 0.5 | 32 | 6 | 32 |
Meropenem | 84 | 14.3 | 100 | 0 | 75.4 | 1 | 32 | 6 | 32 |
Tigecycline | 34.7c | 14.3 | 100 | 0 | 33.3c | 0.032 | 24 | 0.38 | 6 |
Colistin | 6.1d | 100 | NDd | 0 | 17.5d | 0.06 | 64 | 0.25 | 32 |
Fosfomycin | 22 | 0 | 100 | 0 | 23 | 0.125 | 1024 | 12 | 128 |